NCT07403188Recruiting

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Kyverna Therapeutics

Start Date

11/24/2025

Completion Date

1/1/2041

Summary

The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Provided informed consent for the LTFU study * Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol Exclusion Criteria: * Not applicable

Interventions

DRUG

KYV-101

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Refractory Lupus NephritisMyasthaenia GravisStiff Person SyndromeRheumatoid Arthritis (RA)Multiple SclerosisDermatomyositisSystemic Sclerosis (SSc)

Locations

University of Colorado, Denver

Denver, Colorado 80045

United States